Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis

RMD Open

Volumn 3, Issue 1, 2017, Pages

  Emery, Paul ^a   Blanco, Ricardo ^b   Maldonado Cocco, Jose ^c   Chen, Ying Chou ^d   Gaich, Carol L ^e   Delozier, Amy M ^e   De Bono, Stephanie ^e   Liu, Jiajun ^e   Rooney, Terence ^e   Chang, Cecile Hsiao Chun ^e   Dougados, Maxime ^f  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e ELI LILLY AND COMPANY   (United States)

^f INSTITUT NECKER ENFANTS MALADES   (France)

Author keywords

DMARDs (synthetic); Patient perspective; Rheumatoid Arthritis

Indexed keywords

BARICITINIB; PLACEBO;

ADULT; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; EUROQOL 5 DIMENSION INDEX SCORE; FEMALE; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE SCORE; FUNCTIONAL STATUS; FUNCTIONAL STATUS ASSESSMENT; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HUMAN; JOINT STIFFNESS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PAIN ASSESSMENT; PATIENT GLOBAL ASSESSMENT OF DISEASE ACTIVITY; PATIENT-REPORTED OUTCOME; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SHORT FORM 36; TREATMENT RESPONSE; VISUAL ANALOG SCALE; WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE RHEUMATOID ARTHRITIS;

EID: 85016139591     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2016-000410     Document Type: Article

References (40)

1. Carr A, Hewlett S, Hughes R, et al. Rheumatology outcomes: the patient's perspective. J Rheumatol 2003;30:880-3.
2. Klarenbeek NB, Güler-Yüksel M, van der Kooij SM, et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis 2011;70:1039-46.
3. Strand V, Cohen S, Crawford B, et al. Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis. Rheumatology (Oxford) 2004;43:640-7.
4. Taylor PC, Moore A, Vasilescu R, et al. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int 2016;36:685-95.
5. Kosinski M, Kujawski SC, Martin R, et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. Am J Manag Care 2002;8:231-40.
6. Pollard L, Choy EH, Scott DL. The consequences of rheumatoid arthritis: quality of life measures in the individual patient. Clin Exp Rheumatol2005;23(Suppl 39):S43-52.
7. Scott DL, Smith C, Kingsley G. What are the consequences of early rheumatoid arthritis for the individual? Best Pract Res Clin Rheumatol 2005;19A 17-36.
8. Sherrer YS, Bloch DA, Mitchell DM, et al. The development of disability in rheumatoid arthritis. Arthritis Rheum 1986;29:494-500.
9. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheum 2016;68:1-26.
10. Sanderson T, Morris M, Calnan M, et al. What outcomes from pharmacologic treatments are important to people with rheumatoid arthritis? Creating the basis of a patient core set. Arthritis Care Res (Hoboken) 2010;62:640-6.
11. Orbai AM, Bingham CO III. Patient reported outcomes in rheumatoid arthritis clinical trials. Curr Rheumatol Rep 2015;17:28.
12. Gossec L, Dougados M, Dixon W. Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open 2015;1: e000019.
13. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. http://www.fda.gov/downloads/Drugs/../Guidances/UCM193282.pdf
14. Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
15. Sokka T. Morning stiffness and other patient-reported outcomes of rheumatoid arthritis in clinical practice. Scand J Rheumatol Suppl 2011;125:23-7.
16. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
17. OShea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 2013;368:161-70.
18. Dougados M, van der Heijde D, Chen YC, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 2017;76:88-95.
19. Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol2005;23(Suppl 39):S14-18.
20. Ramey DR, Fries JF, Singh G. The Health Assessment Questionnaire 1995: status and review. In: Spiker B, ed. Quality of life andpharmacoeconomics in clinical trials. 2nd edn. Philadelphia: Lippincott-Raven, 1996:227-37.
21. Wells GA, Tugwell P, Kraag GR, et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557-60.
22. Cella D, Yount S, Sorensen M, et al. Validation of the functional assessment of chronic illness therapy fatigue scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 2005;32:811-19.
23. Keystone E, Burmester GR, Furie R, et al. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 2008;59:785-93.
24. Strand V, Burmester GR, Zerbini CA, et al. Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial. Arthritis Care Res (Hoboken) 2015;67:475-83.
25. Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992;305:160-4.
26. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-83.
27. Kosinski M, Zhao SZ, Dedhiya S, et al. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43:1478-87.
28. Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs 2010;70:121-45.
29. EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
30. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53-72.
31. EuroQol Group. EQ-5D-5L User Guide. Version 1.0. April 2011. http://www.euroqol.org/fileadmin/user-upload/Documenten/PDF/Folders-Flyers/UserGuide-EQ-5D-5L.pdf (accessed 1 Jul 2012).
32. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727-36.
33. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353-65.
34. Smolen JS, Kremer JM, Gaich CL, et al. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). Ann Rheum Dis 2016;76:694-700.
35. Schiff M, Takeuchi T, Gaich C, et al. Patient-reported outcomes from a phase 3 study of baricitinib in patients with early rheumatoid arthritis who had received limited or no treatment with disease-modifying anti-rhuematic drugs. Ann Rheum Dis 2016;75 (Suppl 2):419.
36. Keystone EC, Taylor PC, Tanaka Y, et al. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in patients with active rheumatoid arthritis and an inadequate response to background methotrexate therapy. Ann Rheum Dis 2016;75(Suppl 2):412-13.
37. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11.
38. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144: 865-76.
39. Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010;69:1629-35.
40. Strand V, Kremer JM, Gruben D, et al. Tofacitinib in combination with conventional DMARDs in patients with active rheumatoid arthritis: PROs from a phase 3 randomized controlled trial. Arthritis Care Res (Hoboken) 2016. doi:10.1002/acr. 23004